Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation

Edwards Lifesciences Corp is currently experiencing a price increase, aligning with significant upward movement in the Health Care Equipment sector...

Edwards Lifesciences sees price rise amid sector gains. CFO Ullem Scott B. purchases 7,700 shares, signaling confidence ahead of Fed rate cuts.

Edwards Lifesciences Corp experienced a positive shift in market sentiment today, reflected by endorsements from multiple analysts. UBS and Wells F...

Analysts endorse Edwards Lifesciences, boosting price targets. UBS, Wells Fargo, Stifel, and RBC show strong confidence in future performance.

Edwards Lifesciences Corp has projected 8%-10% sales growth for 2026, alongside significant innovation milestones in heart therapies. During its an...

Edwards Lifesciences projects 8%-10% sales growth for 2026, citing key heart therapy innovations. It reaffirms 2025 EPS guidance of 2.56 to 2.62.

Edwards Lifesciences Corp is currently experiencing a price increase, moving higher alongside the Health Care Equipment sector. BTIG has reiterated...

Edwards Lifesciences gains as BTIG maintains "Buy" at $100. Align Technology's rise suggests shared positive market response.

Edwards Lifesciences Corp experienced a stock price increase of 1.4% on Tuesday. On November 10, 2025, executives executed notable stock sales. Dan...

Edwards Lifesciences executives sold significant shares, indicating confidence in market conditions. This strategic selling aligns with planned tra...

Edwards Lifesciences Corp is experiencing an uptick in its stock price, aligning with the broader market's positive movement. The company recently...

Edwards Lifesciences partners with AHA to combat heart valve disease. This collaboration aims to enhance treatment and awareness, boosting healthca...

Edwards Lifesciences Corp is currently experiencing a price increase, coinciding with a notable rise in the Health Care Equipment sector. Truist Se...

Edwards Lifesciences' price increase aligns with positive sector trends and revised price targets, indicating strong performance potential despite...

Edwards Lifesciences Corp is currently experiencing a decline, reflecting broader trends in the Health Care Equipment sub-sector. The company is tr...

Edwards Lifesciences faces sector decline but analysts remain optimistic. Strong earnings beat expectations, prompting raised EPS guidance and posi...

Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and...

Edwards Lifesciences beats quarterly estimates on strength in heart devices

Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a suc...

Edwards Lifesciences CFO Scott Ullem to step down by mid-2026

Edwards Lifesciences Corp is set to conduct its Q3 2025 earnings conference call today at 5:00 PM ET. Analysts project an earnings per share (EPS)...

Edwards Lifesciences' Q3 call today reflects rising EPS estimates. Strong performance from Align Technology may influence investor sentiment.

Edwards Lifesciences Corp has recently received significant upgrades from analysts. Jefferies has raised its rating from Hold to Buy, increasing th...

Analysts upgraded Edwards Lifesciences due to strong earnings expectations. Positive sentiment follows Teradyne's success, boosting confidence in E...

Edwards Lifesciences Corp has seen its stock price increase by 2.0% today. Truist Securities has maintained a Hold rating on the company, raising i...

Edwards Lifesciences' stock gains follow positive trial results. Truist's price target increase reflects growing confidence amid upcoming earnings.

Edwards Lifesciences Corp presented new data at the Transcatheter Cardiovascular Therapeutics conference, showcasing the long-term performance of i...